Contact Us
Drug Search Results
More Filters [+]

PCV-13

Alternative Names: pcv-13, pcv13, pcv 13
Latest Update: 2025-01-09
Latest Update Note: Clinical Trial Update

Product Description

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23) (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25810327/)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PCV-13

Countries in Clinic: Canada, China, Indonesia

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Communicable Diseases|Pneumococcal Infections|Pneumonia, Pneumococcal

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PRO-PCV-3001

P3

Recruiting

Communicable Diseases|Pneumococcal Infections

2025-03-12

PCV13-004

P3

Active, not recruiting

Pneumococcal Infections

2025-03-01

PRO-PCV-1002

P1

Recruiting

Communicable Diseases|Pneumococcal Infections

2025-02-15

PRO-PCV-1001

P1

Completed

Pneumococcal Infections

2024-05-26

Recent News Events

Date

Type

Title

11/07/2024

News Article

 Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

07/30/2024

News Article

 Merck Announces Second-Quarter 2024 Financial Results

06/17/2024

News Article

 U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

05/11/2024

PubMed

 Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.

05/08/2024

PubMed

 The impact of pneumococcal serotype replacement on the effectiveness of a national immunization program: a population-based active surveillance cohort study in New Zealand.

05/03/2024

PubMed

 Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study.

04/26/2024

News Article

 CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions